Mixed-model repeated-measures analyses showed significant ( P < 0.05 ) and/or clinically meaningful improvements ( small to moderate ) from baseline in favor of trametinib for global health ; physical , role , and social functioning ; fatigue ; pain ; insomnia ; nausea and vomiting ; constipation ; dyspnea ; and appetite at weeks 6 and/or 12 .